论文部分内容阅读
目的:探讨健脾疏肝颗粒对链脲佐菌素(STZ)糖尿病模型小鼠的药理作用和作用机制。方法:小鼠分为空白对照组(CNTL)、空白干预组(JPSG)、模型对照组(STZ)、药物低剂量组、高剂量组(STZ+JPSGD、STZ+JPSGG)各6,6,12,12,12只,健脾疏肝颗粒或纯化水灌胃20 d,检测小鼠空腹血糖(FBG)、胰岛素(FINS)、血脂、胰高血糖素、超氧化物歧化酶(SOD)、丙二醛(MDA)、谷胱甘肽过氧化物酶(GSH-Px),计算胰岛素抵抗指数(HOMA-IR),以及胰高血糖素样肽-1(GLP-1)表达情况。结果:与模型对照组比较,STZ+JPSGD组、STZ+JPSGG组小鼠FBG、FINS、HOMA-IR、血脂、胰高血糖素均显著趋于正常,SOD、MDA、GSH-Px活性明显改善,GLP-1表达接近空白对照组,差异具有统计学意义(P<0.05或P<0.01)。结论:健脾疏肝颗粒对STZ模型小鼠具有明显降糖、降脂作用,作用机制可能通过抗氧化作用、调节GLP-1表达和FINS、胰高血糖素水平来发挥作用,值得进一步研究。
Objective: To investigate the pharmacological action and mechanism of Jianpi Shugan granule on streptozotocin (STZ) diabetic mice. Methods: The mice were divided into three groups: control group (CNTL), blank intervention group (JPSG), model control group (STZ), low dose group and high dose group (STZ + JPSGD, STZ + JPSGG) , 12,12, Jianpi Shugan granule or purified water were given for 20 days. The levels of fasting blood glucose (FBG), insulin (FINS), blood lipids, glucagon and superoxide dismutase (SOD) (MDA), glutathione peroxidase (GSH-Px), calculated insulin resistance index (HOMA-IR), and glucagon-like peptide-1 (GLP- Results: Compared with the model control group, the activities of FBG, FINS, HOMA-IR, lipids and glucagon in STZ + JPSGD group and STZ + JPSGG group were significantly increased, SOD, MDA and GSH- GLP-1 expression close to the blank control group, the difference was statistically significant (P <0.05 or P <0.01). Conclusion: Jianpi Shugan Granule has obvious hypoglycemic and hypolipidemic effect on STZ model mice. The mechanism may be through antioxidation, regulating the expression of GLP-1, FINS, glucagon level, which deserves further study.